Cell Therapy for Multiple Sclerosis

Pamela Sarkar, Claire Rice, Neil Scolding

Research output: Contribution to journalArticle (Academic Journal)peer-review

12 Citations (Scopus)
367 Downloads (Pure)


Cell therapy is considered a promising potential treatment for multiple sclerosis, perhaps particularly for the progressive form of the disease for which there are currently no useful treatments. Over the past two decades or more, much progress has been made in understanding the biology of MS and in the experimental development of cell therapy for this disease. Three quite distinct forms of cell therapy are currently being pursued. The first seeks to use stem cells to replace damaged myelin-forming oligodendrocytes within the CNS; the second aims, in effect, to replace the individual’s misfunctioning immune system, making use of haematopoietic stem cells; and the third seeks to utilise endogenous stem cell populations by mobilisation with or without in vitro expansion, exploiting their various reparative and neuroprotective properties. In this article we review progress in these three separate areas, summarising the experimental background and clinical progress thus far made.
Original languageEnglish
Pages (from-to)453-469
Number of pages17
JournalCNS Drugs
Issue number6
Early online date10 Apr 2017
Publication statusPublished - Jun 2017


  • Alemtuzumab
  • Cell Therapy
  • Multiple Sclerosis Patient
  • Experimental Autoimmune Encephalomyelitis
  • Multiple Sclerosis


Dive into the research topics of 'Cell Therapy for Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this